SIREN : 789754454
G2D PHARMA is a French company founded 13 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in LOGNES (77185), this company of category PME shows in 2024 a revenue of 155 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 155 306 € | N/C | 1 204 363 € | 1 683 220 € | 1 252 027 € | 1 052 967 € | 1 022 240 € | 1 098 795 € | 1 061 374 € |
| Net income | -71 034 € | -18 122 € | 24 919 € | 93 563 € | 54 351 € | 13 540 € | 24 539 € | 55 947 € | 26 047 € |
| EBITDA | -66 535 € | N/C | 94 801 € | 185 342 € | 136 908 € | 81 317 € | 89 383 € | 130 895 € | 116 113 € |
| Net margin | -45.7% | N/C | 2.1% | 5.6% | 4.3% | 1.3% | 2.4% | 5.1% | 2.5% |
In 2024, G2D PHARMA achieves revenue of 155 k€. Revenue is declining over the period 2016-2024 (CAGR: -21.4%). After deducting consumption (0 €), gross margin stands at 155 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -67 k€, representing -42.8% of revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -71 k€ (-45.7% of revenue), which will impact equity.
155 306 €
155 306 €
-66 535 €
-72 011 €
-71 034 €
-35.8%
The debt ratio (= Financial debt / Equity x 100) stands at 73%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 52%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
73.077%
51.523%
-35.304%
-1.565
60.8%
In 2024, the debt ratio of G2D PHARMA (73.08) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of G2D PHARMA (51.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of G2D PHARMA (-1.56) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 840.37. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
840.369
-2.635
In 2024, the liquidity ratio of G2D PHARMA (840.37) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of G2D PHARMA (-2.6x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 57 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 45 days. The company must finance 12 days of gap between collections and payments. Inventory turnover is 6 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 99 days of revenue, i.e. 43 k€ to permanently finance. Notable WCR improvement over the period (-86%), freeing up cash.
42 883 €
57 j
45 j
6 j
99 j
Compare G2D PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of G2D PHARMA in 2024 is 155 k€.
G2D PHARMA recorded a net loss in 2024.
The headquarters of G2D PHARMA is located in LOGNES (77185), in the department Seine-et-Marne.
The tax return of G2D PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
G2D PHARMA operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.